The Phase 3 EVOKE Plus study (NCT04777409), investigating semaglutide in people with Early Alzheimer's Disease, reached its primary completion on 2025-09-15. This milestone indicates that the final data collection for the primary outcome measure has concluded for this significant clinical trial.
Background
The study, formally titled "A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)," aims to determine if semaglutide has a positive effect on the progression of Early Alzheimer's Disease. Semaglutide is a well-known medication, also marketed under brand names such as Wegovy, Ozempic, and Rybelsus, primarily used for other indications.
Trial design
The EVOKE Plus study (NCT04777409) is a Phase 3 clinical trial that enrolled 1840 participants with Early Alzheimer's Disease. Participants were randomized to receive either semaglutide or a placebo. The study design included a treatment period lasting up to 173 weeks (approximately 3 years and 4 months), with multiple clinic visits and tests to monitor participant health and disease progression.
What this means
The primary completion of the EVOKE Plus trial signifies the conclusion of the main data collection phase for the study's primary outcomes. Researchers will now proceed with data analysis to evaluate the efficacy and safety profile of semaglutide in the context of Early Alzheimer's Disease. The results are highly anticipated, as they could provide crucial insights into potential new therapeutic strategies for this challenging condition.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The status for study NCT04777409, titled "A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)," was updated to reflect primary completion on 2025-09-15 on clinicaltrials.gov.